This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Validity of estimate of measure of effectiveness
The measure of effectiveness was derived from a before-and-after study. This study design is more prone to bias and confounding than prospective randomised controlled trials. The authors acknowledged that one of the study's limitations was that the number of patients meeting their pre-programme target (i.e. on pravastatin) may have been underestimated. This was because the measure of previous drug use was estimated from pharmacy records, which may not accurately reflect patient adherence.
The study design was appropriate to the study hypothesis. However, a randomised comparison of drug swapping may have been more valid as an indicator of the clinical effectiveness. The clinical data were analysed using appropriate nonparametric statistical methods, although no allowance was made for possible confounding. For example, there could have been a time trend, whereby prior treatment with pravastatin had effects beyond its cessation. Also, there could have been other changes, for example in patient behaviour, which were responsible for some of the change.
The measure of effectiveness, the percentage reaching their LDL cholesterol target, seems to have been appropriate given that it reflected guidelines apparently directly related to the risk of CHD and other atherosclerotic diseases. Its precise value depends partly on the value of risk reduction in these diseases, relative to other quality of life factors. It also depends on it reflecting sufficiently the change in risk due to the drug; i.e. other physiological changes do not lead to confounding.
Validity of estimate of measure of benefit
There was no summary measure of benefit.
Validity of estimate of costs
It was difficult to assess the validity of the cost estimate since the resource use and unit costs were not reported separately. However, all relevant cost categories appear to have been included, considering that the study was undertaken from the perspective of the health care payer.
Other issues
The authors compared their results with those of other relevant studies. The proportion of patients with well-controlled LDL cholesterol levels was comparable to other studies in similar populations. The issue of generalisability was not explicitly addressed. The authors suggested that the results may be transferred to other Veterans Affairs Centres. This would only be valid if other centres achieved the same discount on the drug costs from the manufacturer.
